Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study-Reference-Cited by-同舟云学术

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

Published:2018-05-22 Issue:8 Volume:33 Page:1397-1406
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

McClung Michael R¹²,Brown Jacques P³,Diez-Perez Adolfo⁴,Resch Heinrich⁵,Caminis John⁶,Meisner Paul⁶,Bolognese Michael A⁷,Goemaere Stefan⁸,Bone Henry G⁹,Zanchetta Jose R¹⁰,Maddox Judy¹¹,Bray Sarah¹²,Grauer Andreas¹¹

Affiliation:

1. Oregon Osteoporosis Center; Portland OR USA

2. Australian Catholic University; Melbourne Australia

3. Laval University and CHU de Québec Research Centre; Quebec City QC Canada

4. Medicine Hospital del Mar/IMIM; Autonomous University of Barcelona; Barcelona Spain

5. St Vincent Hospital; Vienna Austria

6. UCB Pharma; Brussels Belgium

7. Bethesda Health Research Center; Bethesda MD USA

8. Ghent University Hospital; Gent Belgium

9. Michigan Bone and Mineral Clinic; Detroit MI USA

10. Instituto de Investigaciones Metabólicas; Buenos Aires Argentina

11. Amgen Inc.; Thousand Oaks CA USA